Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mnemosyne Pharmaceuticals Inc.

Selective NMDA modulators for neuropsychiatric disorders

This article was originally published in Start Up

Executive Summary

Less than half of patients with major depressive disorder respond to current therapies; that’s why clinical studies showing that the anesthetic medication ketamine benefitted MDD patients within hours made headlines, despite ketamine’s serious drawbacks. Mnemosyne Pharmaceuticals Inc. has identified a highly selective oral compound that hits the same target as ketamine but with less of the effects that can lead to abuse.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC092597

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel